Preferentially expressed Antigen in Melanoma (PRAME), also known as CT130 (cancer testis antigen 130), MAPE (melanoma antigen preferentially expressed in tumours), and OIP-4 (Opa-interacting protein 4) [1], belongs to the cancer/testis antigen (CTA) gene family [2] and encodes a membrane-bound protein recognised by T lymphocytes, which is a cancer-testis antigen that was first identified in 1997 in cutaneous melanoma by Ikeda et al. [3]. The gene discussed is PRAME; the disease is melanoma.